Literature DB >> 9893187

Nocturnal asthma is associated with reduced glucocorticoid receptor binding affinity and decreased steroid responsiveness at night.

M Kraft1, E Vianna, R J Martin, D Y Leung.   

Abstract

BACKGROUND: The mechanisms for heightened nocturnal inflammation in patients with nocturnal asthma (NA) are not well understood.
OBJECTIVE: We sought to determine the glucocorticoid receptor (GR) characteristics and steroid responsiveness in subjects with NA.
METHODS: Eleven subjects with NA, 12 subjects with nonnocturnal asthma (NNA), and 16 nonasthmatic control subjects underwent blood sampling at 4 pm and 4 am in a random order separated by 1 week. GR binding affinity was measured in PBMCs by using a [3H]-dexamethasone (DX) radioligand binding assay and Scatchard analysis. The capacity of hydrocortisone (HC) and DX to suppress proliferation of PBMCs stimulated with PHA was also determined.
RESULTS: The subjects with NA exhibited a significantly lower GR binding affinity at 4 am, detected by an elevated dissociation constant (Kd) of 22.2 +/- 1.6 nmol/L compared with Kd at 4 pm (10.9 +/- 0.7 nmol/L; P =.0001). The GR Kd of the NNA and control groups did not change significantly from 4 pm to 4 am. Within the NA group, there was also a significant inverse correlation between the absolute FEV1 at 4 am and the Kd at 4 am (r = -0.65, P =.04). PBMCs from subjects with NA exhibited less suppression of PBMC proliferation with HC and DX at 4 am compared with that at 4 pm (P =.0004 and.03 for HC and DX, respectively). There were no circadian changes in suppression of PBMC proliferation in either the NNA or control groups.
CONCLUSION: GR binding affinity and steroid responsiveness exhibit a circadian variation in subjects with NA, with a reduced GR binding affinity and suppression of PBMC proliferation at 4 am that is not observed in normal subjects or asthmatic subjects without nocturnal exacerbation. These observations may contribute to nocturnal airway inflammation by inhibiting the antiinflammatory effects of glucocorticoids.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9893187     DOI: 10.1016/s0091-6749(99)70527-0

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  10 in total

1.  Sleep and Obstructive Lung Diseases.

Authors:  Michael E Ezzie; Jonathan P Parsons; John G Mastronarde
Journal:  Sleep Med Clin       Date:  2008-12

Review 2.  Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2 agonists?

Authors:  T D Holimon; C C Chafin; T H Self
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  Nocturnal asthma: underlying mechanisms and treatment.

Authors:  E Rand Sutherland
Journal:  Curr Allergy Asthma Rep       Date:  2005-03       Impact factor: 4.806

4.  Influence of the Circadian System on Disease Severity.

Authors:  Mikhail Litinski; Frank Ajl Scheer; Steven A Shea
Journal:  Sleep Med Clin       Date:  2009-06-01

5.  Rapid effect of inhaled steroids on nocturnal worsening of asthma.

Authors:  G Frezza; J Terra-Filho; J A B Martinez; E O Vianna
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

6.  [Relevance of sleep for patients with lung diseases].

Authors:  H F Becker
Journal:  Internist (Berl)       Date:  2004-09       Impact factor: 0.743

7.  Nocturnal thoracoabdominal asynchrony in house dust mite-sensitive nonhuman primates.

Authors:  Xiaojia Wang; Shaun Reece; Stephen Olmstead; Robert L Wardle; Michael R Van Scott
Journal:  J Asthma Allergy       Date:  2010-07-28

Review 8.  Small airway inflammation in asthma.

Authors:  M K Tulic; P Christodoulopoulos; Q Hamid
Journal:  Respir Res       Date:  2001-08-10

9.  New insights into the pathophysiology of the small airways in asthma.

Authors:  Qutayba Hamid; Meri K Tulic
Journal:  Ann Thorac Med       Date:  2007-01       Impact factor: 2.219

10.  Effects of physical exercise training on nocturnal symptoms in asthma: Systematic review.

Authors:  Cristina de Oliveira Francisco; Swati Anil Bhatawadekar; Jessica Babineau; W Darlene Reid; Azadeh Yadollahi
Journal:  PLoS One       Date:  2018-10-22       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.